Difficulties on the way to introducing HPV vaccination
Abstract
For cervical cancer, which in 99.7% of cases is caused by human papillomavirus (HPV), the primary prevention is vaccination against the infection. The HPV vaccines available today are safe and effective. Countries that have added HPV vaccine to their National Calendar have reported decreases in cervical cancer and other cancers caused by the human papillomavirus. However, there are a number of obstacles to the introduction of the vaccine. This article analyzes the main barriers to mass HPV vaccination.
About the Authors
K. S. Korsak
УО «Гомельский государственный медицинский университет»
Russian Federation
Russian Federation
E. V. Voropaev
УО «Гомельский государственный медицинский университет»
Russian Federation
Russian Federation
References
1. Affordable human papillomavirus screening needed to eradicate cervical cancer for all / S. Krivacsy [et al.] // The Lancet Global Health. - 2019. - Vol. 7, No 12. - P. 1605-1606. doi: 10.1016/S2214-109X(19)30423-1
2. HPV vaccines can be the hallmark of cancer prevention / S. Sanjose [et al.] // The Lancet. - 2019. - Vol. 394, No 10197. - P. 450-451. doi: 10.1016/S0140-6736(19)30549-5
3. Assessment of eight HPV vaccination programs implemented in lowest income countries /j. Ladner [et al.] // BMC Public Health. - 2012. - Vol. 12. - P. 370. doi: 10.1186/1471-2458-12-370
4. Вакцины и вакцинация. Национальное руководство. Краткое издание / под ред. В.В. Зверева, Р.М. Хаитова. - Мщсква : ГЭОТАР-Медиа, 2014. - 640 с.
5. Discrepancies in the evaluation of the safety of the human papillomavirus vaccine /j.L. Cervantes [et al.] // Memorias do Instituto Oswaldo Cruz. - 2018. - Vol. 113, No 8. - P. 180063. doi: 10.1590/0074-02760180063
6. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials / M. Arbyn [et al.] // Expert Review Vaccines. - 2018. - Vol. 17, No 12. - P. 1085-1091. doi: 10.1080/14760584.2018.1548282
7. Is HPV vaccination in pregnancy safe? / U. Bonde [et al.] Human Vaccines & Immunotherapeutics. - 2016. - Vol. 12, No 8. - P. 1960-1964. doi:10.1080/21645515.2016.1160178
8. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy / F. Carozzi [et al.] // BMC Infectious Diseases. - 2018. - Vol. 18, No 1. - P. 38. doi: 10.1186/s12879-018-2945-8
9. Non-Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection / M. Saccucci [et al.] // Sexually Transmitted Diseases. - 2018. - Vol. 45, no 4. - P. 260-265. doi: 10.1097/OLQ.0000000000000731
10. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? / C. Patel [et al.] // Eurosurveillance. - 2018. - Vol. 23, No 41. - P. 1700737. doi: 10.2807/1560-7917.ES.2018.23.41.1700737
11. Substantial Decline in Prevalence of Vaccine-Type and Nonvaccine-Type Human Papillomavirus (HPV) in Vaccinated and Unvaccinated Girls 5 Years After Implementing HPV Vaccine in Norway / B. Feiring [et al.] // The Journal of Infectious Diseases. - 2018. - Vol. 218, No 12. - P. 1900-1910. doi: 10.1093/infdis/jiy432
12. Sexual Activity-Related Outcomes After Human Papillomavirus Vaccination of 11- to 12-Year-Olds / R.A. Bednarczyk [et al.] // Pediatrics. - 2012. - Vol. 130, No 5. - P. 798-805. doi: 10.1542/peds.2012-1516)
13. Safety and perception: What are the greatest enemies of HPV vaccination programmes? / P. Bonanni [et al.] // Vaccine. - 2018. - Vol. 36, No 36. - P. 5424- 5429. doi: 10.1016/j.vaccine.2017.05.071
14. Parenting Style and the Timing of Jewish Adolescents’ Sexual Debut / R. Etzkin [et al.] // Journal of Youth Development. - 2010. - Vol. 5, No 2. - P. 17. doi: 10.5195/jyd.2010.216
15. Knowledge and Attitudes Towards Human Papillomavirus (HPV) Among Academic and Community Physicians in Mangalore, India / C. Canon [et al.] // Cancer Education. - 2017. - Vol. 32, No 2. - P. 382-391. doi: 10.1007/s13187-016-0999-0
16. Parents’ uptake of human papillomavirus vaccines for their children: a systematic review and meta-analysis of observational studies / P.A. Newman [et al.] // BMJ Open. - 2018. - Vol. 8, No 4. doi: 10.1136/bmjopen-2017-019206
17. No Association between HPV Vaccination and Infertility in U.S. Females 18-33 Years Old / N.B. Schmuhl [et al.] // Vaccine. - 2020. - Vol. 38, No 24. - P. 4038- 4043. doi:10.1016/j.vaccine.2020.03.035
18. HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa / H. Tuominen [et al.] // Scientific Reports. - 2018. - Vol. 8, No 1. - P. 9787. doi:10.1038/s41598-018-27980-3
19. Juvenile-Onset Recurrent Respiratory Papillomatosis Diagnosis and Management - A Developing Country Review / R. Seedat // Pediatric Health, Medicine and Therapeutics. - 2020. - Vol. 11. - P. 39-46. doi:10.2147/PHMT.S200186
20. Paediatric virology and human papillomaviruses: An update / I.N. Mammas [et al.] // Experimental and Therapeutic Medicine. - 2019. - Vol. 17, No 6. - P. 4337-4343. doi: 10.3892/etm.2019.7516
21. Recurrent respiratory papillomatosis: A state-of-the-art review / H.R. Fortes [et al.] // Respiratory Medicine. - 2017. - Vol. 126. - P. 116-121. doi:10.1016/j.rmed.2017.03.030
22. Is HPV the Novel Target in Male Idiopathic Infertility? A Systematic Review of the Literature / F. Muscianisi [et al.] // Frontiers in Endocrinology. - 2021. - Vol. 12. doi: 10.3389/fendo.2021.643539
23. Idiopathic male infertility and human papillomavirus infection / K.S. Ibishev [et al.] // Vestnik Urologii. - 2019. - Vol. 7, No 2. - P. 51-58. doi: 10.21886/2308-6424-2019-7-2-51-58
24. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): Health system experiences and prospects /j. Wigle [et al.] // Vaccine. - 2013. - Vol. 31, No 37. - P. 3811-3817. doi: 10.1016/j.vaccine.2013.06.016
25. Is one dose of human papillomavirus vaccine as effective as three? : A national cohort analysis /j.M.L. Brotherton [et al.] // Papillomavirus Research. - 2019. - Vol. 8. doi: 10.1016/j.pvr.2019.100177
26. Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact / V. Gilca [et al.] // Vaccine. - 2018. - Vol. 36, No 32. - P. 4800-4805. doi:10.1016/j.vaccine.2018.02.004
27. Towards the global elimination of cervical cancer / K. Canfell // Papillomavirus Research. - 2019. - Vol. 8. - P. 100170. doi: 10.1016/j.pvr.2019.100170
28. General practitioners’ attitudes and behaviors toward HPV vaccination: A French national survey / F. Collange [et al.] // Vaccine. - 2016. - Vol. 34, No 6. - P. 762-768. doi: 10.1016/j.vaccine.2015.12.054
Review
For citations:
Korsak K.S., Voropaev E.V. Difficulties on the way to introducing HPV vaccination. Medical and Biological Problems of Life Activity. 2022;(1):99-104. (In Russ.)
Views: 139
Email this article 